Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Data Presented At Society Of Nuclear Medicine 2009 Annual Meeting Supports Potential Of Peregrine's Cotara(R) For The Treatment Of Brain Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. The results reported from an ongoing dosimetry study at U.S. brain cancer centers show that in patients dosed in the first two cohorts of the study, the concentration of Cotara in brain tumors was on average more than 300-fold higher than in other normal organs. In addition, these patients have all either met or exceeded the expected median survival time of six months for recurrent GBM patients. Cotara is currently being tested in this Phase I dose response and dosimetry trial and in a Phase II clinical trial in recurrent GBM patients.
generic viagra online
Radiotherapy Link To Breast Cancer And Heart Disease Found
Scientists have found a way to identify breast cancer patients at risk of heart disease after radiotherapy, according to a report published yesterday.
News of the day
Smoking, High Blood Pressure And Diabetes In Mid-life Can Lead To Dementia
Middle aged people who smoke, have high blood pressure or diabetes are far more likely to develop dementia in later life, suggests research published ahead of print in the Journal of Neurology, Neurosurgery and Psychiatry.
Nutrition

QuantRx Announces FluoroPharma To Present Phase I Study Results Of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer

QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced that its affiliate, FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled (PET) tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto. The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT). BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually. About QuantRx Biomedical QuantRx Biomedical Corporation (OTCBB: QTXB) is a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by healthcare professionals and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care. The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company"s technology portfolio, with more than three dozen patents, patents pending and licensed patents, includes: (1) RapidSense® point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets; (2) PAD technology for over-the-counter applications, and the diagnosis and treatment of women"s health concerns and other medical needs, and (3) significant investments in: (a) genome-based diagnostic chips for the laboratory and healthcare professional markets; and (b) molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment. FluoroPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009